Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Medicare Advantage usage trends reveal slight declines in 2023, highlighting critical insights for policymakers amid rising ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.